Condition: Breast Cancer · Sponsor: SCRI Development Innovations, LLC
This clinical trial is evaluating tucatinib in combination with Doxil in participants with human epidermal growth factor 2 positive (HER2+) locally advanced or metastatic breast cancer. The main goals of this study are to: * Learn how well the combination of tucatinib and Doxil works * Learn more about the side effects of the combination of tucatinib and Doxil
This description comes directly from the study's public registry record.
Sarah Cannon Development Innovations · 1-844-710-6157 · SCRI.InnovationsMedical@scri.com
Always discuss trial participation with your own doctor first.
| Maryland Oncology Hematology | Columbia, Maryland, United States | Recruiting |
| Alliance Cancer Specialists | Bensalem, Pennsylvania, United States | Recruiting |
| SCRI Oncology Partners | Nashville, Tennessee, United States | Recruiting |
| Tennessee Oncology | Nashville, Tennessee, United States | Active Not Recruiting |
| Texas Oncology- DFW | Dallas, Texas, United States | Recruiting |
| Texas Oncology- San Antonio | San Antonio, Texas, United States | Recruiting |
| Virginia Oncology Associates | Norfolk, Virginia, United States | Recruiting |
| Blue Ridge Cancer Care (Oncology & Hematology Assoc of SW Virginia, Inc) | Salem, Virginia, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05748834